Developer docs
API playgroundTry for free, no card

Search company profiles

Cmbio

Full company profile

uuid00hhkvq

Namestring
Cmbio
Legal namestring
Cmbio
Websiteurl
cmbio.io
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cmbio is a Copenhagen-headquartered microbiome and multi-omics research services company formed through the fusion of four specialized firms — Clinical Microbiomics, CosmosID, DNASense, and MS-Omics. It serves academic researchers, pharmaceutical and biotech companies, healthcare and clinical organizations, food safety producers, and environmental/agricultural research groups, delivering end-to-end laboratory analysis and data interpretation for human, animal, and environmental health applications. The company employs a team of over 100 experts spanning microbiology, bioinformatics, metabolomics, molecular biology, and data science, operating laboratories in Denmark and the United States with commercial reach across US, EU, and APAC regions.

Technically, Cmbio's offering is organized into three pillars: (1) Omics sequencing services including shotgun and long-read metagenomics, 16S rRNA/marker gene analysis, microbiome profiling, absolute abundance, metabolomics, transcriptomics/metatranscriptomics, proteomics, and metaproteomics; (2) Bioinformatics services including biostatistics, integrative systems biology/multi-omics integration, strain tracking and engraftment, and machine learning/AI analysis; and (3) the Cosmos-HUB (CosmosID-HUB) cloud-based bioinformatics platform for scalable data analysis and visualization. Differentiated technical components include proprietary Clonal-Level Microbiomics for strain-level resolution, GxP-compliant laboratory processes for regulatory-ready clinical and pharmaceutical work, and eDNA metabarcoding for environmental species identification.

Commercially, Cmbio operates as a B2B research-services business with a consultative, direct field-sales motion in which specialized scientists collaborate with clients on study design, method selection, and data interpretation. Revenue is generated primarily through project-based professional services (contract sequencing and bioinformatics), sampling kits and project handling, and access to the Cosmos-HUB software platform. Pricing is quote-based and not publicly disclosed, varying by sample type, sample count, sequencing depth, analysis requirements, and project complexity, with inbound demand captured via "Request a meeting" forms and direct contact; the company is GDPR-compliant and operates under Danish jurisdiction.

Short descriptiontext

Cmbio provides laboratory sequencing, bioinformatics, and cloud-based data analysis services for microbiome and multi-omics research, serving academic, pharmaceutical, clinical, food safety, and environmental clients across human, animal, and environmental health applications from labs in Denmark and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome sequencing services, multi-omics analysis, bioinformatics data analysis, metagenomics research, strain-level identification
Industry5 codes
PRIMARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Microbiome Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Microbiome Research Services
TypeProfessional Services
Description

End-to-end microbiome research services including sequencing (metagenomics, metabolomics, transcriptomics, proteomics), bioinformatics analysis, and project handling. Services are provided on a contract basis with specialized scientists collaborating directly with clients on analytical techniques, method selection, and data interpretation.

cmbio.io
2Bioinformatics and Data Analysis
TypeSubscription Recurring
Description

Advanced bioinformatics services including biostatistics, integrative systems biology, multi-omics integration, strain tracking, and machine learning/AI-powered analysis. Provided as standalone services or integrated with sequencing services.

cmbio.io
3Sampling Kits and Project Handling
TypeHardware Sales
Description

Custom kits for efficient microbiome sample collection, preservation, and transport tailored to study needs and logistics. Includes kitting services for research projects.

cmbio.io
4Software Platform (Cosmos-HUB)
TypeSubscription Recurring
Description

Cloud-based software platform for microbiome data analysis available to researchers and companies for their own analysis needs

cmbio.io
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on sample type, number of samples, sequencing depth, analysis requirements, and project complexity. Direct consultation with scientific team required for quote.

cmbio.io
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Cosmos-HUB
Description

Cloud-based bioinformatics platform for microbiome data analysis

cmbio.io
+2 more records
Core offering1 text field

Cmbio provides end-to-end microbiome and multi-omics laboratory services, including shotgun metagenomics, long-read metagenomics, marker gene analysis, metabolomics, transcriptomics, proteomics, and metaproteomics sequencing, complemented by advanced bioinformatics analysis and the Cosmos-HUB cloud platform for scalable data interpretation. The company serves researchers and organizations across human health, animal health, and environmental applications through a consultative sales model with specialized scientists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • eDNA sampling identifies more species than traditional methods (42 fish species vs 33 via trawl nets)
+3 more records
Product overview1 text field

Cmbio is a unified multi-omics services platform formed by the fusion of Clinical Microbiomics, CosmosID, DNASense, and MS-Omics. The company provides end-to-end microbiome research services organized into three main pillars: (1) Omics Services including shotgun metagenomics, long-read metagenomics, marker gene analysis, microbiome profiling, metabolomics, transcriptomics, proteomics, and metaproteomics; (2) Bioinformatics Services including integrative systems biology, biostatistics, strain tracking, and machine learning/AI services; and (3) Software Platform through Cosmos-HUB for cloud-based data analysis. Services span human health, animal health, and environmental applications including gut microbiome research, eDNA metabarcoding, food safety, and agriculture. The architecture combines laboratory sequencing services with advanced bioinformatics and AI-powered analytics delivered through a cloud-based platform.

Product and service1 record
1Cosmos-HUB
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

CosmosID is one of the founding companies that merged to form Cmbio. CosmosID's technology and capabilities in microbial sequencing and bioinformatics are integrated into Cmbio's service offerings, including the CosmosID-HUB platform for microbiome analysis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Provides CLC bio, microbial genomics, and clinical bioinformatics software plus companion services — comparable through its bioinformatics platform and growing microbiome/wet-lab offerings, anchored by a much larger installed base.

TypeDirect peer
Description

Multi-omics services company providing sequencing, metabolomics, and bioinformatics across microbiome, transcriptomics, and epigenetics — overlaps substantially with Cmbio's omics and bioinformatics service lines.

3Diversigen
TypeDirect peer
Description

Microbiome sequencing and analysis services company focused on DNA/RNA extraction, library prep, sequencing, and custom bioinformatics — directly comparable services and customer profile to Cmbio, now within OraSure.

TypeDirect peer
Description

Provides microbiome collection devices, DNA extraction kits, and shotgun metagenomic sequencing services — directly comparable to Cmbio's sampling-kit-plus-sequencing services for academic and clinical microbiome customers.

TypeBroad incumbent
Description

Large genomics CRO offering microbial whole-genome sequencing, metagenomics, and bioinformatics with global lab capacity — directly competes in multi-omics project services, often at lower price points.

TypeBroad incumbent
Description

Eurofins acquired CoreBiome to offer end-to-end microbial genomics services alongside a global lab network; comparable as a full-service microbiome sequencing and bioinformatics provider, but embedded in a much broader testing portfolio.

TypeBroad incumbent
Description

Dominant sequencing platform vendor whose instruments and BaseSpace/cloud ecosystem shape the competitive set Cmbio operates in — vertical integration threats make it a relevant adjacent incumbent despite its different primary business.

TypeEmerging player
Description

The CosmosID brand that merged into Cmbio and contributed the Cosmos-HUB platform; included for context as the same technology stack now marketed under Cmbio, with overlap on microbial identification databases.

TypeDirect peer
Description

Offers shotgun metagenomics, 16S amplicon sequencing, metatranscriptomics, metabolomics, and bioinformatics services to researchers and pharma — a near-direct multi-omics services competitor with similar project-based, quote-driven GTM.

TypeDirect peer
Description

Specializes in microbial identification and microbiome sequencing services using 16S and shotgun approaches, with bioinformatics reporting — comparable mid-sized microbiome CRO serving academic and industrial researchers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cmbio

Microbiome Research Servicescmbio.io

Cmbio provides laboratory sequencing, bioinformatics, and cloud-based data analysis services for microbiome and multi-omics research, serving academic, pharmaceutical, clinical, food safety, and environmental clients across human, animal, and environmental health applications from labs in Denmark and the US.

What Cmbio does

Cmbio is a Copenhagen-headquartered microbiome and multi-omics research services company formed through the fusion of four specialized firms — Clinical Microbiomics, CosmosID, DNASense, and MS-Omics. It serves academic researchers, pharmaceutical and biotech companies, healthcare and clinical organizations, food safety producers, and environmental/agricultural research groups, delivering end-to-end laboratory analysis and data interpretation for human, animal, and environmental health applications. The company employs a team of over 100 experts spanning microbiology, bioinformatics, metabolomics, molecular biology, and data science, operating laboratories in Denmark and the United States with commercial reach across US, EU, and APAC regions.

Technically, Cmbio's offering is organized into three pillars: (1) Omics sequencing services including shotgun and long-read metagenomics, 16S rRNA/marker gene analysis, microbiome profiling, absolute abundance, metabolomics, transcriptomics/metatranscriptomics, proteomics, and metaproteomics; (2) Bioinformatics services including biostatistics, integrative systems biology/multi-omics integration, strain tracking and engraftment, and machine learning/AI analysis; and (3) the Cosmos-HUB (CosmosID-HUB) cloud-based bioinformatics platform for scalable data analysis and visualization. Differentiated technical components include proprietary Clonal-Level Microbiomics for strain-level resolution, GxP-compliant laboratory processes for regulatory-ready clinical and pharmaceutical work, and eDNA metabarcoding for environmental species identification.

Commercially, Cmbio operates as a B2B research-services business with a consultative, direct field-sales motion in which specialized scientists collaborate with clients on study design, method selection, and data interpretation. Revenue is generated primarily through project-based professional services (contract sequencing and bioinformatics), sampling kits and project handling, and access to the Cosmos-HUB software platform. Pricing is quote-based and not publicly disclosed, varying by sample type, sample count, sequencing depth, analysis requirements, and project complexity, with inbound demand captured via "Request a meeting" forms and direct contact; the company is GDPR-compliant and operates under Danish jurisdiction.

Cmbio firmographics

Firmographics
Name
Cmbio
Legal name
Cmbio
Website
https://cmbio.io
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Cmbio provides laboratory sequencing, bioinformatics, and cloud-based data analysis services for microbiome and multi-omics research, serving academic, pharmaceutical, clinical, food safety, and environmental clients across human, animal, and environmental health applications from labs in Denmark and the US.
Ownership category
akta.pro rank

Cmbio industry classification

Industry
Product category
Microbiome Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Microbiome sequencing services
  • Multi-omics analysis
  • Bioinformatics data analysis
  • Metagenomics research
  • Strain-level identification

Where Cmbio is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

Cmbio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Microbiome Research Services: End-to-end microbiome research services including sequencing (metagenomics, metabolomics, transcriptomics, proteomics), bioinformatics analysis, and project handling. Services are provided on a contract basis with specialized scientists collaborating directly with clients on analytical techniques, method selection, and data interpretation.
  2. Bioinformatics and Data Analysis: Advanced bioinformatics services including biostatistics, integrative systems biology, multi-omics integration, strain tracking, and machine learning/AI-powered analysis. Provided as standalone services or integrated with sequencing services.
  3. Sampling Kits and Project Handling: Custom kits for efficient microbiome sample collection, preservation, and transport tailored to study needs and logistics. Includes kitting services for research projects.
  4. Software Platform (Cosmos-HUB): Cloud-based software platform for microbiome data analysis available to researchers and companies for their own analysis needs

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Cmbio product offering

Product offering

Core offering

Cmbio provides end-to-end microbiome and multi-omics laboratory services, including shotgun metagenomics, long-read metagenomics, marker gene analysis, metabolomics, transcriptomics, proteomics, and metaproteomics sequencing, complemented by advanced bioinformatics analysis and the Cosmos-HUB cloud platform for scalable data interpretation. The company serves researchers and organizations across human health, animal health, and environmental applications through a consultative sales model with specialized scientists.

Product overview

Cmbio is a unified multi-omics services platform formed by the fusion of Clinical Microbiomics, CosmosID, DNASense, and MS-Omics. The company provides end-to-end microbiome research services organized into three main pillars: (1) Omics Services including shotgun metagenomics, long-read metagenomics, marker gene analysis, microbiome profiling, metabolomics, transcriptomics, proteomics, and metaproteomics; (2) Bioinformatics Services including integrative systems biology, biostatistics, strain tracking, and machine learning/AI services; and (3) Software Platform through Cosmos-HUB for cloud-based data analysis. Services span human health, animal health, and environmental applications including gut microbiome research, eDNA metabarcoding, food safety, and agriculture. The architecture combines laboratory sequencing services with advanced bioinformatics and AI-powered analytics delivered through a cloud-based platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Cosmos-HUB: Cloud-based bioinformatics platform for microbiome data analysis
  • CosmosID
  • Clonal-Level Microbiomics

Products and services

  • Cosmos-HUB

Quantifiable outcome

  • eDNA sampling identifies more species than traditional methods (42 fish species vs 33 via trawl nets)
  • +3 more outcomes

Companies that use Cmbio

Customer profile

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Cmbio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Cmbio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CosmosIDcoreOthersCosmosID is one of the founding companies that merged to form Cmbio. CosmosID's technology and capabilities in microbial sequencing and bioinformatics are integrated into Cmbio's service offerings, including the CosmosID-HUB platform for microbiome analysis.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Cmbio competitors and assessment

Company assessment

Broad incumbents

  • QIAGEN Digital Insights: Provides CLC bio, microbial genomics, and clinical bioinformatics software plus companion services — comparable through its bioinformatics platform and growing microbiome/wet-lab offerings, anchored by a much larger installed base.
  • Novogene: Large genomics CRO offering microbial whole-genome sequencing, metagenomics, and bioinformatics with global lab capacity — directly competes in multi-omics project services, often at lower price points.
  • Eurofins Genomics (CoreBiome): Eurofins acquired CoreBiome to offer end-to-end microbial genomics services alongside a global lab network; comparable as a full-service microbiome sequencing and bioinformatics provider, but embedded in a much broader testing portfolio.
  • Illumina (sequencing and BaseSpace): Dominant sequencing platform vendor whose instruments and BaseSpace/cloud ecosystem shape the competitive set Cmbio operates in — vertical integration threats make it a relevant adjacent incumbent despite its different primary business.

Direct peers

  • LC Sciences: Multi-omics services company providing sequencing, metabolomics, and bioinformatics across microbiome, transcriptomics, and epigenetics — overlaps substantially with Cmbio's omics and bioinformatics service lines.
  • Diversigen: Microbiome sequencing and analysis services company focused on DNA/RNA extraction, library prep, sequencing, and custom bioinformatics — directly comparable services and customer profile to Cmbio, now within OraSure.
  • Zymo Research: Provides microbiome collection devices, DNA extraction kits, and shotgun metagenomic sequencing services — directly comparable to Cmbio's sampling-kit-plus-sequencing services for academic and clinical microbiome customers.
  • CD Genomics: Offers shotgun metagenomics, 16S amplicon sequencing, metatranscriptomics, metabolomics, and bioinformatics services to researchers and pharma — a near-direct multi-omics services competitor with similar project-based, quote-driven GTM.
  • MRDNA (Molecular Research): Specializes in microbial identification and microbiome sequencing services using 16S and shotgun approaches, with bioinformatics reporting — comparable mid-sized microbiome CRO serving academic and industrial researchers.

Emerging players

  • CosmosID (legacy brand inside Cmbio): The CosmosID brand that merged into Cmbio and contributed the Cosmos-HUB platform; included for context as the same technology stack now marketed under Cmbio, with overlap on microbial identification databases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Cmbio social profiles

Digital presence

Cmbio compliance and trust

Trust signal

Compliance1 record

Cmbio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cmbio leadership team

Management profile

Number of profiles

Cmbio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cmbio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cmbio

What does Cmbio do?

Cmbio provides end-to-end microbiome and multi-omics laboratory services, including shotgun metagenomics, long-read metagenomics, marker gene analysis, metabolomics, transcriptomics, proteomics, and metaproteomics sequencing, complemented by advanced bioinformatics analysis and the Cosmos-HUB cloud platform for scalable data interpretation. The company serves researchers and organizations across human health, animal health, and environmental applications through a consultative sales model with specialized scientists.

Is Cmbio a public or private company?

Cmbio is a private company. It is classified as unknown and is currently operating.

When was Cmbio founded?

Cmbio was founded in 2015. It employs 101 to 250 people.

Where is Cmbio based?

Cmbio is headquartered in Copenhagen, Denmark, in the Europe region.

How does Cmbio make money?

Four revenue lines are on record. Microbiome Research Services are the primary driver. The others are bioinformatics and Data Analysis, sampling Kits and Project Handling and software Platform (Cosmos-HUB).

Who are Cmbio's main competitors?

Broad incumbents on record are QIAGEN Digital Insights, Novogene, Eurofins Genomics (CoreBiome) and Illumina (sequencing and BaseSpace). Direct peers are LC Sciences, Diversigen, Zymo Research, CD Genomics and MRDNA (Molecular Research). CosmosID (legacy brand inside Cmbio) is listed as an emerging player.

Does Cmbio have an API?

No public API is recorded for Cmbio.

What industry is Cmbio in?

Cmbio's product category is Microbiome Research Services. Its primary akta.pro industry code is HLAGANAH, Microbiome & Metagenomics Services, with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
nutraingredients-usa.comNew partnership to advance microbiome research and personalize health careNimble Science and Cmbio announced a partnership to integrate Nimble's SIMBA ingestible capsule data into Cmbio's multi-omics services. The collaboration aims to advance microbiome research and personalized medicine, with Cmbio also acquiring Eagle Genomics' software platform.Business & FinancialCmbio® Acquires Eagle Genomics' Assets To Enhance Multi-Omics Software And AI/ML Capabilities Of Its Digital Biology Platform.Cmbio acquired Eagle Genomics' e[datascientist] software and related intellectual property through an asset sale agreement. The acquisition aims to enhance Cmbio's multi-omics software and AI/ML capabilities for digital biology. The deal aligns with Cmbio's mission to advance multi-omics science and technology.YahooCmbio® Acquires Eagle Genomics' Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.Cmbio acquired Eagle Genomics' e[datascientist] software platform through an asset sale agreement with CBW Recovery LLP and Eagle Genomics Limited. The deal includes all intellectual property and aligns with Cmbio's multi-omics science mission. The acquisition expands Cmbio's technology suite and strengthens its position in multi-omics services.YahooCmbio® Acquires Eagle Genomics' Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.Cmbio acquired Eagle Genomics' e[datascientist] software platform through an asset sale agreement with CBW Recovery LLP and Eagle Genomics Limited. The deal includes all intellectual property and aligns with Cmbio's multi-omics science mission. The acquisition expands Cmbio's technology suite and strengthens its position in multi-omics services.CmbioCmbio® Acquires Eagle Genomics' Assets to Enhance Multi-Omics SoftwareCmbio has acquired the e[datascientist] software platform and related intellectual property from Eagle Genomics Limited, which is currently in administration. This transaction allows Cmbio to expand its multi-omics technology suite by integrating Eagle Genomics' cloud-based bioinformatics and AI/ML capabilities.PR NewswireCmbio® Acquires Eagle Genomics' Assets to Enhance Multi-Omics Software and AI/ML capabilities of its Digital Biology Platform.Cmbio® has acquired the e[datascientist]™ software platform and associated intellectual property from Eagle Genomics Limited through an asset sale agreement with CBW Recovery LLP. This strategic acquisition is intended to enhance Cmbio’s multi-omics science capabilities by integrating advanced bioinformatics and AI/ML tools into its digital biology platform.Clinical-MicrobiomicsExperts in Advanced Laboratory ServicesCmbio, a microbiome company, specializes in advanced laboratory services and multi-omics research aimed at improving health, agriculture, and environmental sustainability. With a team of over 100 experts and a global presence, the company focuses on delivering regulatory-ready data for various applications, driving advancements in healthcare, nutrition, and environmental sectors. Their innovative approach integrates high-resolution microbial identification and AI-driven insights to support significant scientific developments.